Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vanda ( (VNDA) ) has issued an announcement.
On March 10, 2026, Vanda Pharmaceuticals CEO Mihael Polymeropoulos appeared on Fox Business to discuss the company’s pricing and commercial strategy for NEREUSTM, its newly U.S. FDA-approved treatment for preventing vomiting caused by motion. He disclosed that Vanda is developing NEREUSRXTM, a direct-to-consumer channel for accessing NEREUSTM, and indicated the drug is expected to become commercially available in the next few months.
The announcement underscores Vanda’s move to pair a conventional drug launch with a dedicated direct-to-consumer platform, which could broaden patient access and strengthen its competitive position in the motion-sickness treatment market. The planned rollout timeline and channel strategy signal an acceleration of NEREUSTM’s path to market, with potential implications for prescribers, patients seeking convenient access options, and investors tracking the company’s commercialization progress.
The most recent analyst rating on (VNDA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Vanda stock, see the VNDA Stock Forecast page.
Spark’s Take on VNDA Stock
According to Spark, TipRanks’ AI Analyst, VNDA is a Neutral.
The score is held down primarily by weak financial performance—large losses, significant cash burn, and declining equity—despite low leverage. Technical indicators also point to a bearish trend. These negatives are partially offset by constructive 2026 growth guidance and recent regulatory progress, but management’s expectation of higher cash burn and product headwinds temper the outlook.
To see Spark’s full report on VNDA stock, click here.
More about Vanda
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines, including NEREUSTM, a drug recently approved in the U.S. for the prevention of vomiting induced by motion. The company targets patients affected by motion-related disorders and is pursuing both traditional and direct-to-consumer channels to expand access to its therapies.
Average Trading Volume: 2,914,356
Technical Sentiment Signal: Buy
Current Market Cap: $513.1M
See more insights into VNDA stock on TipRanks’ Stock Analysis page.